1
|
Eldin C, Nurtop E, Coiffard B, Colombini N, Ninove L, Priet S, Barthélémy K, Reynaud-Gaubert M, de Lamballerie X. Correspondence: serum neutralization of SARS-CoV-2 Omicron sublineages BA.1, BA.2 and BA.5 in lung transplant recipients receiving prophylactic tixagevimab/cilgavimab. Infection 2024:10.1007/s15010-024-02258-1. [PMID: 38584221 DOI: 10.1007/s15010-024-02258-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Accepted: 04/02/2024] [Indexed: 04/09/2024]
Affiliation(s)
- Carole Eldin
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France.
- Comité de Lutte Contre les Infections Nosocomiales (CLIN) Équipe Opérationnelle d'Hygiène (EOH), Hôpital Nord, Assistance-Publique Hôpitaux de Marseille, Marseille, France.
| | - Elif Nurtop
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| | - Benjamin Coiffard
- Service de Pneumologie et Équipe de Transplantation Pulmonaire, Centre de Ressources et de Compétences de la Mucoviscidose (CRCM) Adulte, AP-HM Hôpital Nord, 13015, Marseille, France
- Aix Marseille Université, Marseille, France
| | - Nathalie Colombini
- Pharmacy Department, North Hospital, Public Hospitals of Marseille, Aix-Marseille University, Marseille, France
| | - Laetitia Ninove
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| | - Stéphane Priet
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| | - Karine Barthélémy
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| | - Martine Reynaud-Gaubert
- Service de Pneumologie et Équipe de Transplantation Pulmonaire, Centre de Ressources et de Compétences de la Mucoviscidose (CRCM) Adulte, AP-HM Hôpital Nord, 13015, Marseille, France
- Aix Marseille Université, Marseille, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| |
Collapse
|
2
|
Inchauste L, Nurtop E, Brisbarre N, Ninove L, Gallian P, de Lamballerie X, Priet S. Exploring cell-free assays for COVID-19 serosurvey. Sci Rep 2024; 14:6096. [PMID: 38480769 PMCID: PMC10938000 DOI: 10.1038/s41598-024-55852-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Accepted: 02/28/2024] [Indexed: 03/17/2024] Open
Abstract
Serosurveys to monitor immunity toward COVID-19 in the population are primarily performed using an ELISA to screen samples for SARS-CoV-2 antibodies, followed by confirmation by a virus neutralization test, which is considered the Gold Standard. However, virus neutralization test may not be feasible for some laboratories because of the requirement for specific facilities and trained personnel. In an attempt to address this limitation, we evaluated three cell-free methods as potential alternatives for assessing SARS-CoV-2 seroprevalence in human population from plasma. We report the establishment of two inhibition ELISAs designed to detect anti-Spike RBD IgG antibodies and a microsphere quantitative suspension array technology assay, based on the Luminex xMAP platform, to measure the presence of antibodies against various SARS-CoV-2 antigens, including anti-RBD. These methods were also compared to a commercial chemiluminescent immunoassay designed for anti-RBD antibodies detection and to the combined ELISA + virus neutralization test strategy. These cell-free assays performed equally to estimate the percentage of positive and negative samples and could be used to determine the prevalence of SARS-CoV-2 antibodies in human population, at least in cohort with high-expected prevalence, without the use of seroneutralization assay.
Collapse
Affiliation(s)
- Lucia Inchauste
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| | - Elif Nurtop
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| | - Nadège Brisbarre
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
- Établissement Français du Sang Provence Alpes Côte d'Azur et Corse, Marseille, France
| | - Laetitia Ninove
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| | - Pierre Gallian
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
- Établissement Français du Sang, La Plaine Saint-Denis, Saint-Denis, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| | - Stéphane Priet
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France.
| |
Collapse
|
3
|
Touret F, Martin-Blondel G, de Lamballerie X, Dupont A, Izopet J, Mentré F, Kamar N, Autran B, Paintaud G, Caillard S, Richez C, Couzi L, Xhaard A, Marjanovic Z, Avouac J, Jacquet C, Anglicheau D, Cheminant M, Yazdanpanah Y, N'Guyen S, Terrier B, Gottenberg JE, Besson C, Letrou S, Kali S, Angoulvant D, Barthélémy K, Priet S, Nurtop E, Sanchez VP, Tardivon C, Blancho G, Le Bourgeois A, Lévy V. Low to undetectable Omicron BQ.1.1 neutralization by patient's sera a month after initiation of AZD7442 600 mg. J Infect 2023; 86:e126-e129. [PMID: 36750165 DOI: 10.1016/j.jinf.2023.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2023] [Accepted: 02/02/2023] [Indexed: 02/07/2023]
Affiliation(s)
- Franck Touret
- Unité des Virus Émergents, INSERM-1207, IRD-190, Aix-Marseille University, France
| | - Guillaume Martin-Blondel
- Service des Maladies Infectieuses et Tropicales, CHU de Toulouse & Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, France
| | | | - Axelle Dupont
- Université Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, F-75018 Paris, France; Centre d'Investigation clinique-Epidémiologie Clinique 1425, Inserm, Hôpital Bichat, Paris, France; Department of Epidemiology Biostatistics and Clinical Research, AP-HP, Hôpital Bichat, Paris, France
| | - Jacques Izopet
- CHU Toulouse, Hôpital Purpan, Laboratoire de Virologie, National Reference Center for Hepatitis E, 31300 Toulouse, France; Inserm UMR 1291, CNRS UMR5051, Université Toulouse III, 31000 Toulouse, France
| | - France Mentré
- Université Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, F-75018 Paris, France; Centre d'Investigation clinique-Epidémiologie Clinique 1425, Inserm, Hôpital Bichat, Paris, France; Department of Epidemiology Biostatistics and Clinical Research, AP-HP, Hôpital Bichat, Paris, France
| | - Nassim Kamar
- Département de Néphrologie et Transplantation d'Organes, CHU Rangueil 31059 Toulouse, France
| | - Brigitte Autran
- Sorbonne-Université, Cimi-Paris, Inserm U1135, CNRS ERL8255, UPMC CR7, Team "NK and T Cell Immunity, Infections and Cancer", Paris, France
| | - Gilles Paintaud
- Université de Tours, EA4245 Transplantation, Immunology and Inflammation, Tours, France
| | - Sophie Caillard
- Department of Nephrology and Transplantation, Strasbourg University Hospital, 67000 Strasbourg, France; Inserm UMR S1109 Labex Transplantex, Fédération de Médecine Translationnelle, Strasbourg University, Strasbourg, France
| | - Christophe Richez
- Hôpital Pellegrin, CHU de Bordeaux, Service de Rhumatologie, Centre de référence des maladies autoimmunes systémiques rares (RESO), UMR-CNRS 5164, Université de Bordeaux, Bordeaux, France
| | - Lionel Couzi
- Nephrologie-Transplantation-Dialyse, CHU Bordeaux, Bordeaux, France; CNRS-UMR 5164 Immuno ConcEpT, Université de Bordeaux, Bordeaux, France
| | - Aliénor Xhaard
- Service d'hématologie greffe Hôpital Saint-Louis, APHP, Université de Paris Cité, Paris, France
| | - Zora Marjanovic
- Sorbonne University, Paris, France; Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Paris, France; INSERM, UMRs 938, Paris, France
| | - Jerome Avouac
- Université de Paris Service de Rhumatologie, Hôpital Cochin, AP-HP, CUP 27 rue du Faubourg Saint-Jacques 75014 Paris, France
| | - Caroline Jacquet
- Service d'Hématologie, CHRU Nancy, Hôpitaux Brabois, Vandoeuvre les Nancy, France
| | - Dany Anglicheau
- Department of Nephrology and kidney transplantation, Necker Hospital, APHP and Université de Paris Cité, Paris, France
| | - Morgane Cheminant
- Clinical Hematology, Necker-Enfants Malades University Hospital, AP-HP, F-75015, Université de Paris Cité, Paris, France
| | | | - Stéphanie N'Guyen
- Sorbonne université, Groupe Hospitalier Pitié-Salpêtrière APHP, Service d'Hématologie clinique, Pavillon Georges Heuyer, 47-83 boulevard de l'Hôpital, 75651 Paris Cedex 13, France; Sorbonne Université, Inserm CNRS 1135 "NK and T Cell Immunity, Virus and Cancer", Centre d'Immunologie et des Pathologies Infectieuses (CIMI), UPMC UMRS CR7-Inserm U1135-CNRS ERL 8255, faculté de Médecine Sorbonne Université, Site Pitié-Salpêtrière, 91 boulevard de l'Hôpital, 75013 Paris, France
| | - Benjamin Terrier
- Assistance Publique-Hôpitaux de Paris, Département de Médecine Interne, Centre de Référence National pour les maladies auto-immunes systémiques rares, Hôpital Cochin Paris, Université Paris, France
| | - Jacques Eric Gottenberg
- Service de Rhumatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; CNR RESO, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France; Laboratoire d'Immunopathologie et de Chimie Thérapeutique, Institut de Biologie Moléculaire et Cellulaire (IBMC), CNRS UPR3572, Strasbourg, France
| | - Caroline Besson
- Université Paris-Saclay, UVSQ, CESP-INSERM1018, CH de Versailles, 78150, Le Chesnay, France
| | - Sophie Letrou
- Département d'Épidémiologie, Biostatistique et Recherche Clinique Unité de Recherche Clinique Paris Nord APHP, Nord - Université Paris Cité Hôpital Bichat - Claude-Bernard 46 rue Henri Huchard, 75877 Paris Cedex 18, France
| | - Sabrina Kali
- Clinical Research Department, ANRS|Emerging infectious disease, PariSanté Campus, 2 rue d'Oradour-sur-Glane, 75015 Paris, France
| | - Denis Angoulvant
- Service de Cardiologie, CHRU de Tours & EA4245 Transplantation Immunologie et Inflammation, Université de Tours, F37000 Tours, France
| | - Karine Barthélémy
- Unité des Virus Émergents, INSERM-1207, IRD-190, Aix-Marseille University, France
| | - Stéphane Priet
- Unité des Virus Émergents, INSERM-1207, IRD-190, Aix-Marseille University, France
| | - Elif Nurtop
- Unité des Virus Émergents, INSERM-1207, IRD-190, Aix-Marseille University, France
| | | | - Coralie Tardivon
- Department of Epidemiology Biostatistics and Clinical Research, AP-HP, Hôpital Bichat, Paris, France; Centre d'Investigation clinique-Epidémiologie Clinique 1425, Inserm, Hôpital Bichat, Paris, France
| | - Gilles Blancho
- Institut de Transplantation- Urologie - Néphrologie (ITUN) Hôtel Dieu - CHU de Nantes, 30 bd Jean-Monnet, 44093 Nantes, France
| | - Amandine Le Bourgeois
- Service d'hématologie clinique, CHU Nantes, 1 place Alexis Ricordeau, 44000 Nantes, France
| | - Vincent Lévy
- Département de Recherche Clinique, Hôpital Avicenne, APHP, Université Sorbonne Paris Nord and CRESS INSERM U1153, ECSTRRA Team, Paris, France.
| |
Collapse
|
4
|
Gallian P, Hozé N, Brisbarre N, Saba Villarroel PM, Nurtop E, Isnard C, Pastorino B, Richard P, Morel P, Cauchemez S, de Lamballerie X. SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021. iScience 2023; 26:106222. [PMID: 36818722 PMCID: PMC9930380 DOI: 10.1016/j.isci.2023.106222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Revised: 12/20/2022] [Accepted: 02/11/2023] [Indexed: 02/17/2023] Open
Abstract
We conducted a cross-sectional study for SARS-CoV-2 anti-S1 IgG prevalence in French blood donors (n = 32605), from March-2020 to January-2021. A mathematical model combined seroprevalence with a daily number of hospital admissions to estimate the probability of hospitalization upon infection and determine the number of infections while correcting for antibody decay. There was an overall seroprevalence increase over the study period and we estimate that ∼15% of the French population had been infected by SARS-CoV-2 by January-2021. The infection/hospitalization ratio increased with age, from 0.31% (18-30yo) to 4.5% (61-70yo). Half of the IgG-S1 positive individuals had no detectable antibodies 4 to 5 months after infection. The seroprevalence in group O donors (7.43%) was lower (p = 0.003) than in A, B, and AB donors (8.90%). We conclude, based on seroprevalence data and mathematical modeling, that a large proportion of the French population was unprotected against severe disease prior to the vaccination campaign.
Collapse
Affiliation(s)
- Pierre Gallian
- Établissement Français du Sang, La Plaine Saint Denis 93218, France.,Unité des Virus Émergents (UVE: Aix-Marseille University - IRD 190 - Inserm 1207), 13005 Marseille, France
| | - Nathanaël Hozé
- Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université Paris Cité, UMR2000, CNRS, 75015 Paris, France
| | - Nadège Brisbarre
- Unité des Virus Émergents (UVE: Aix-Marseille University - IRD 190 - Inserm 1207), 13005 Marseille, France.,Établissement Français du Sang Provence Alpes Côte d'Azur et Corse, 13005 Marseille France
| | | | - Elif Nurtop
- Unité des Virus Émergents (UVE: Aix-Marseille University - IRD 190 - Inserm 1207), 13005 Marseille, France
| | - Christine Isnard
- Unité des Virus Émergents (UVE: Aix-Marseille University - IRD 190 - Inserm 1207), 13005 Marseille, France.,Établissement Français du Sang Provence Alpes Côte d'Azur et Corse, 13005 Marseille France
| | - Boris Pastorino
- Unité des Virus Émergents (UVE: Aix-Marseille University - IRD 190 - Inserm 1207), 13005 Marseille, France
| | - Pascale Richard
- Établissement Français du Sang, La Plaine Saint Denis 93218, France
| | - Pascal Morel
- Établissement Français du Sang, La Plaine Saint Denis 93218, France.,UMR RIGHT 1098, Inserm, Établissement Français du Sang, University of Franche-Comté, 25000 Besançon, France
| | - Simon Cauchemez
- Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université Paris Cité, UMR2000, CNRS, 75015 Paris, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE: Aix-Marseille University - IRD 190 - Inserm 1207), 13005 Marseille, France
| |
Collapse
|
5
|
Gallian P, Brisbarre N, Nurtop E, Le Cam S, Franck T, Isnard C, Malard L, Laperche S, Richard P, Morel P, Tiberghien P, de Lamballerie X. Low neutralization capacity against SARS-CoV-2 Omicron BQ.1.1 of convalescent plasma collected during circulation of Omicron BA.1. Vox Sang 2023; 118:407-408. [PMID: 36897221 DOI: 10.1111/vox.13418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2023] [Revised: 02/23/2023] [Accepted: 02/23/2023] [Indexed: 03/11/2023]
Affiliation(s)
- Pierre Gallian
- Établissement Français du Sang, Saint Denis, France.,Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-INSERM 1207), Marseille, France
| | - Nadége Brisbarre
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-INSERM 1207), Marseille, France.,Établissement Français du Sang Provence Alpes Côte d'Azur et Corse, Marseille, France
| | - Elif Nurtop
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-INSERM 1207), Marseille, France
| | | | - Touret Franck
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-INSERM 1207), Marseille, France
| | - Christine Isnard
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-INSERM 1207), Marseille, France.,Établissement Français du Sang Provence Alpes Côte d'Azur et Corse, Marseille, France
| | | | - Syria Laperche
- Établissement Français du Sang, Saint Denis, France.,Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-INSERM 1207), Marseille, France
| | | | - Pascal Morel
- Établissement Français du Sang, Saint Denis, France.,UMRRIGHT 1098, Inserm, Établissement Français du Sang, University of Franche-Comté, Besançon, France
| | - Pierre Tiberghien
- Établissement Français du Sang, Saint Denis, France.,Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-INSERM 1207), Marseille, France.,Établissement Français du Sang Provence Alpes Côte d'Azur et Corse, Marseille, France.,UMRRIGHT 1098, Inserm, Établissement Français du Sang, University of Franche-Comté, Besançon, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-INSERM 1207), Marseille, France
| |
Collapse
|
6
|
Decarreaux D, Sevila J, Masse S, Capai L, Fourié T, Villarroel PMS, Amroun A, Nurtop E, Vareille M, Blanchon T, de Lamballerie X, Charrel R, Falchi A. Eight Months of Serological Follow-Up of Anti-SARS-CoV-2 Antibodies in France: A Study among an Adult Population. Int J Environ Res Public Health 2022; 19:15257. [PMID: 36429974 PMCID: PMC9691066 DOI: 10.3390/ijerph192215257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 11/10/2022] [Accepted: 11/14/2022] [Indexed: 06/16/2023]
Abstract
BACKGROUND Uncertainties remain regarding the nature and durability of the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). AIM This study investigated immunoglobulin G response and neutralizing activity to evaluate the mean antibody concentrations and response duration induced by each vaccination regimen in a French adult population. METHODS A study including blood sampling and questionnaires was carried out from November 2020 to July 2021 with three separate follow-up phases. Spike proteins and neutralizing antibodies were quantified using ELISA and a virus-neutralization test. RESULTS Overall, 295 participants were included. Seroprevalences were 11.5% (n = 34), 10.5% (n = 31), and 68.1% (n = 201) in phases 1, 2, and 3, respectively. Importantly, 5.8% (n = 17) of participants lost their natural antibodies. Antibody response of participants with only a prior infection was 88.2 BAU/mL, significantly lower than those vaccinated, which was 1909.3 BAU/mL (p = 0.04). Moreover, the antibody response of vaccinated participants with a prior infection was higher (3593.8 BAU/mL) than those vaccinated without prior infection (3402.9 BAU/mL) (p = 0.78). Vaccinated participants with or without prior infection had a higher seroneutralization rate (91.0%) than those unvaccinated with prior infection (65.0%). CONCLUSION These results demonstrated that single infection does not confer effective protection against SARS-CoV-2.
Collapse
Affiliation(s)
- Dorine Decarreaux
- Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France
- INSERM, Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique, IPLESP, 75012 Paris, France
- Unité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France
| | - Julie Sevila
- Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France
| | - Shirley Masse
- Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France
| | - Lisandru Capai
- Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France
| | - Toscane Fourié
- Unité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France
| | - Paola Mariela Saba Villarroel
- Unité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France
| | - Abdennour Amroun
- Unité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France
| | - Elif Nurtop
- Unité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France
| | - Matthieu Vareille
- Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France
| | - Thierry Blanchon
- INSERM, Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique, IPLESP, 75012 Paris, France
| | - Xavier de Lamballerie
- Unité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France
| | - Remi Charrel
- Unité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France
| | - Alessandra Falchi
- Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France
| |
Collapse
|
7
|
Kayabolen A, Akcan U, Özturan D, Ulbegi‐Polat H, Sahin GN, Pinarbasi‐Degirmenci N, Bayraktar C, Soyler G, Sarayloo E, Nurtop E, Ozer B, Guney‐Esken G, Barlas T, Yildirim IS, Dogan O, Karahuseyinoglu S, Lack NA, Kaya M, Albayrak C, Can F, Solaroglu I, Bagci‐Onder T. Protein Scaffold-Based Multimerization of Soluble ACE2 Efficiently Blocks SARS-CoV-2 Infection In Vitro and In Vivo. Adv Sci (Weinh) 2022; 9:e2201294. [PMID: 35896894 PMCID: PMC9353362 DOI: 10.1002/advs.202201294] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/05/2022] [Revised: 06/03/2022] [Indexed: 06/15/2023]
Abstract
Soluble ACE2 (sACE2) decoys are promising agents to inhibit SARS-CoV-2, as their efficiency is unlikely to be affected by escape mutations. However, their success is limited by their relatively poor potency. To address this challenge, multimeric sACE2 consisting of SunTag or MoonTag systems is developed. These systems are extremely effective in neutralizing SARS-CoV-2 in pseudoviral systems and in clinical isolates, perform better than the dimeric or trimeric sACE2, and exhibit greater than 100-fold neutralization efficiency, compared to monomeric sACE2. SunTag or MoonTag fused to a more potent sACE2 (v1) achieves a sub-nanomolar IC50 , comparable with clinical monoclonal antibodies. Pseudoviruses bearing mutations for variants of concern, including delta and omicron, are also neutralized efficiently with multimeric sACE2. Finally, therapeutic treatment of sACE2(v1)-MoonTag provides protection against SARS-CoV-2 infection in an in vivo mouse model. Therefore, highly potent multimeric sACE2 may offer a promising treatment approach against SARS-CoV-2 infections.
Collapse
Affiliation(s)
- Alisan Kayabolen
- Koç University Research Center for Translational Medicine (KUTTAM)Koç UniversityIstanbul34450Turkey
| | - Ugur Akcan
- Koç University Research Center for Translational Medicine (KUTTAM)Koç UniversityIstanbul34450Turkey
| | - Doğancan Özturan
- Koç University Research Center for Translational Medicine (KUTTAM)Koç UniversityIstanbul34450Turkey
| | - Hivda Ulbegi‐Polat
- Genetic Engineering and Biotechnology InstituteTUBITAK Marmara Research CenterKocaeli41470Turkey
| | - Gizem Nur Sahin
- Koç University Research Center for Translational Medicine (KUTTAM)Koç UniversityIstanbul34450Turkey
| | | | - Canan Bayraktar
- Koç University Research Center for Translational Medicine (KUTTAM)Koç UniversityIstanbul34450Turkey
| | - Gizem Soyler
- Koç University Research Center for Translational Medicine (KUTTAM)Koç UniversityIstanbul34450Turkey
| | - Ehsan Sarayloo
- Koç University Research Center for Translational Medicine (KUTTAM)Koç UniversityIstanbul34450Turkey
- Department of BiotechnologyBeykoz Institute of Life Sciences and Biotechnology (BILSAB)Bezmialem Vakif UniversityIstanbul34820Turkey
| | - Elif Nurtop
- Koç University Isbank Center for Infectious Diseases (KUISCID)Istanbul34010Turkey
| | - Berna Ozer
- Koç University Isbank Center for Infectious Diseases (KUISCID)Istanbul34010Turkey
| | - Gulen Guney‐Esken
- Koç University Isbank Center for Infectious Diseases (KUISCID)Istanbul34010Turkey
| | - Tayfun Barlas
- Koç University Isbank Center for Infectious Diseases (KUISCID)Istanbul34010Turkey
| | - Ismail Selim Yildirim
- Genetic Engineering and Biotechnology InstituteTUBITAK Marmara Research CenterKocaeli41470Turkey
| | - Ozlem Dogan
- Koç University Isbank Center for Infectious Diseases (KUISCID)Istanbul34010Turkey
- Koç University School of MedicineDepartment of Medical MicrobiologyIstanbul34010Turkey
| | - Sercin Karahuseyinoglu
- Koç University Research Center for Translational Medicine (KUTTAM)Koç UniversityIstanbul34450Turkey
- Koç University School of Medicine, Department of Histology and EmbryologyIstanbul34450Türkiye
| | - Nathan A. Lack
- Koç University Research Center for Translational Medicine (KUTTAM)Koç UniversityIstanbul34450Turkey
- Vancouver Prostate CentreUniversity of British ColumbiaVancouverBC V6H 3Z6Canada
| | - Mehmet Kaya
- Koç University Research Center for Translational Medicine (KUTTAM)Koç UniversityIstanbul34450Turkey
| | - Cem Albayrak
- Koç University Research Center for Translational Medicine (KUTTAM)Koç UniversityIstanbul34450Turkey
- Department of BiotechnologyBeykoz Institute of Life Sciences and Biotechnology (BILSAB)Bezmialem Vakif UniversityIstanbul34820Turkey
| | - Fusun Can
- Koç University Isbank Center for Infectious Diseases (KUISCID)Istanbul34010Turkey
- Koç University School of MedicineDepartment of Medical MicrobiologyIstanbul34010Turkey
| | - Ihsan Solaroglu
- Koç University Research Center for Translational Medicine (KUTTAM)Koç UniversityIstanbul34450Turkey
- Department of Basic SciencesLoma Linda UniversityLoma LindaCA92354USA
| | - Tugba Bagci‐Onder
- Koç University Research Center for Translational Medicine (KUTTAM)Koç UniversityIstanbul34450Turkey
| |
Collapse
|
8
|
Gallian P, Amroun A, Laperche S, Le Cam S, Brisbarre N, Malard L, Nurtop E, Isnard C, Richard P, Morel P, Tiberghien P, de Lamballerie X. Reduced neutralizing antibody potency of COVID-19 convalescent vaccinated plasma against SARS-CoV-2 Omicron variant. Vox Sang 2022; 117:971-975. [PMID: 35577569 PMCID: PMC9347889 DOI: 10.1111/vox.13279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2022] [Revised: 03/21/2022] [Accepted: 03/22/2022] [Indexed: 11/28/2022]
Abstract
Background and Objective The SARS‐CoV‐2 Omicron variant displays increased infectiveness as well as mutations resulting in reduced neutralizing activity of antibodies acquired after vaccination or infection involving earlier strains. To assess the ability of vaccinated COVID‐19 convalescent plasma (CCP‐V) collected before November 2021 to seroneutralize Omicron, we compared neutralizing antibody (nAb) titres of 63 samples against Omicron and earlier B.1 (D614G) strains. Methods and Findings Relationship between anti‐Omicron titres and IgG anti‐S1 levels (binding arbitrary unit: BAU/ml) was studied. Although correlated, anti‐Omicron titres were significantly lower than anti‐B.1 titres (median = 80 [10–1280] vs. 1280 [160–10,240], p < 0.0001). Omicron nAb titres and IgG anti‐S1 levels were correlated (Spearman's rank correlation coefficient = 0.67). Anti‐S1 IgG threshold at 7000 BAU/ml may allow to discard CCP‐V without anti‐Omicron activity (nAb titre <40). Conversely, only those with highest titres (≥160) had systematically anti‐S1 IgG levels >7000 BAU/ml. Conclusion A fraction of CCP‐V collected before November 2021 retains anti‐Omicron seroneutralizing activity that may be selected by quantitative anti‐IgG assays, but such assays do not easily allow the identification of ‘high‐titre’ CCP‐V. However, collecting plasma from vaccinated donors recently infected with Omicron may be the best option to provide optimal CCP‐V for immunocompromised patients infected with this variant.
Collapse
Affiliation(s)
- Pierre Gallian
- Etablissement Français du Sang, La Plaine Saint Denis, France.,Unité des Virus Emergents (UVE: Aix-Marseille Univ, IRD 190, Inserm 1207), Marseille, France
| | - Abdennour Amroun
- Unité des Virus Emergents (UVE: Aix-Marseille Univ, IRD 190, Inserm 1207), Marseille, France
| | - Syria Laperche
- Etablissement Français du Sang, La Plaine Saint Denis, France.,Unité des Virus Emergents (UVE: Aix-Marseille Univ, IRD 190, Inserm 1207), Marseille, France
| | - Sophie Le Cam
- Etablissement Français du Sang, La Plaine Saint Denis, France
| | - Nadège Brisbarre
- Unité des Virus Emergents (UVE: Aix-Marseille Univ, IRD 190, Inserm 1207), Marseille, France.,Etablissement français du Sang Provence Alpes Côte d'Azur et Corse, Marseille, France
| | - Lucile Malard
- Etablissement Français du Sang, La Plaine Saint Denis, France
| | - Elif Nurtop
- Unité des Virus Emergents (UVE: Aix-Marseille Univ, IRD 190, Inserm 1207), Marseille, France
| | - Christine Isnard
- Unité des Virus Emergents (UVE: Aix-Marseille Univ, IRD 190, Inserm 1207), Marseille, France.,Etablissement français du Sang Provence Alpes Côte d'Azur et Corse, Marseille, France
| | - Pascale Richard
- Etablissement Français du Sang, La Plaine Saint Denis, France
| | - Pascal Morel
- Etablissement Français du Sang, La Plaine Saint Denis, France.,UMR RIGHT 1098, Inserm, Etablissement Français du Sang, University of Franche-Comté, Besançon, France
| | - Pierre Tiberghien
- Etablissement Français du Sang, La Plaine Saint Denis, France.,UMR RIGHT 1098, Inserm, Etablissement Français du Sang, University of Franche-Comté, Besançon, France
| | - Xavier de Lamballerie
- Unité des Virus Emergents (UVE: Aix-Marseille Univ, IRD 190, Inserm 1207), Marseille, France
| |
Collapse
|
9
|
Couderc AL, Ninove L, Nouguerède E, Rey D, Rebroin M, Daumas A, Tomasini P, Greillier L, Salas S, Duffaud F, Dahan L, Duluc M, Garcia ME, Pluvy J, Chaléat S, Farnault L, Venton G, Fourié T, Nurtop E, de Lamballerie X, Villani P, Charrel R, Correard F. Acceptance, efficacy, and safety of COVID-19 vaccination in older patients with cancer. J Geriatr Oncol 2022; 13:850-855. [PMID: 35589542 PMCID: PMC9108027 DOI: 10.1016/j.jgo.2022.05.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Revised: 05/04/2022] [Accepted: 05/10/2022] [Indexed: 01/08/2023]
Abstract
Purpose The COVID-19 vaccination campaign began in December 2020, in France, and primarily targeted the oldest people. Our study aimed to determine the level of acceptance of vaccination in a population of older patients with cancer. Methods From January 2021, we offered vaccination with the BNT162b2 COVID-19 vaccine to all patients 70 years and older referred to our geriatric oncology center in Marseille University Hospital (AP-HM) for geriatric assessment before initiation of an oncological treatment. Objectives were to evaluate acceptance rate of COVID-19 vaccination and to assess vaccine safety, reactogenicity, and efficacy two months after the first dose. Results Between January 18, 2021 and May 7, 2021, 150 older patients with cancer were offered vaccination after a geriatric assessment. The majority were men (61.3%), with a mean age of 81 years. The two most frequent primary tumors were digestive (29.4%) and thoracic (18%). The vaccine acceptance rate was 82.6% and the complete vaccination rate (2 doses) reached 75.3%. Among the vaccinated patients, 15.9% reported mild side effects after the first dose and 23.4% after the second dose, mostly arm pain and fatigue. COVID-19 cases were observed in 5.1% of vaccinated patients compared with 16.7% in unvaccinated patients. Of the 22 vaccinated patients who agreed to have their serum tested, 15 had antibodies against the spike protein at day 21 after the first dose. Conclusion Our study showed a high acceptance rate of COVID-19 vaccination, with good tolerance in this frail population. These results highlight the benefits of organizing vaccination campaigns at the very beginning of oncological management in older patients. Clinical trial registration: This study was registered May 23, 2019 in ClinicalTrials.gov (NCT03960593).
Collapse
Affiliation(s)
- Anne-Laure Couderc
- Internal Medicine, Geriatrics and Therapeutic Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France; Aix-Marseille University, CNRS, EFS, ADES, Marseille, France; Coordination Unit for Geriatric Oncology (UCOG), PACA West, France.
| | - Laetitia Ninove
- Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, 13005 Marseille, France
| | - Emilie Nouguerède
- Internal Medicine, Geriatrics and Therapeutic Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France; Coordination Unit for Geriatric Oncology (UCOG), PACA West, France
| | - Dominique Rey
- Internal Medicine, Geriatrics and Therapeutic Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France; Coordination Unit for Geriatric Oncology (UCOG), PACA West, France
| | | | - Aurélie Daumas
- Internal Medicine, Geriatrics and Therapeutic Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France
| | - Pascale Tomasini
- Multidisciplinary Oncology and Therapeutic Innovations Department, AP-HM, Marseille, France
| | - Laurent Greillier
- Multidisciplinary Oncology and Therapeutic Innovations Department, AP-HM, Marseille, France
| | | | | | - Laetitia Dahan
- Hepato-Gastro-Enterolgy Unit, CHU Timone, AP-HM, Marseille, France
| | - Muriel Duluc
- Hepato-Gastro-Enterolgy Unit, CHU Timone, AP-HM, Marseille, France
| | - Marie-Eve Garcia
- Multidisciplinary Oncology and Therapeutic Innovations Department, AP-HM, Marseille, France
| | - Johan Pluvy
- Multidisciplinary Oncology and Therapeutic Innovations Department, AP-HM, Marseille, France
| | - Solène Chaléat
- Multidisciplinary Oncology and Therapeutic Innovations Department, AP-HM, Marseille, France
| | - Laure Farnault
- Haematology and Cellular Therapy Department, AP-HM, Marseille, France
| | - Geoffroy Venton
- Haematology and Cellular Therapy Department, AP-HM, Marseille, France
| | - Toscane Fourié
- Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, 13005 Marseille, France
| | - Elif Nurtop
- Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, 13005 Marseille, France
| | - Xavier de Lamballerie
- Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, 13005 Marseille, France
| | - Patrick Villani
- Internal Medicine, Geriatrics and Therapeutic Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France; Aix-Marseille University, CNRS, EFS, ADES, Marseille, France
| | - Remi Charrel
- Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, 13005 Marseille, France
| | | |
Collapse
|
10
|
Saba Villarroel PM, Castro Soto MDR, Undurraga V, Sanz H, Jaldín AM, Ninove L, Nurtop E, Pezzi L, Mohamed Ali S, Amroun A, Seston M, de Lamballerie X. High SARS-CoV-2 Prevalence among Healthcare Workers in Cochabamba, Bolivia. Viruses 2022; 14:v14020232. [PMID: 35215826 PMCID: PMC8874891 DOI: 10.3390/v14020232] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 01/17/2022] [Accepted: 01/21/2022] [Indexed: 12/14/2022] Open
Abstract
Healthcare workers (HCWs) are at increased risk of SARS-CoV-2 infection. The aim of the study was to estimate the SARS-CoV-2 seroprevalence among HCWs in Cochabamba, Bolivia and to determine the potential risk factors. In January 2021, a cross-sectional SARS-CoV-2 seroprevalence study was conducted in 783 volunteer clinical and non-clinical HCWs in tertiary care facilities. It was based on IgG detection using ELISA, chemiluminiscence, and seroneutralisation tests from dried blood spots. Analysis revealed a high seroprevalence (43.4%) of SARS-CoV-2 IgG antibodies. The combination of anosmia and ageusia (OR: 68.11; 95%-CI 24.83–186.80) was predictive of seropositivity. Belonging to the cleaning staff (OR: 1.94; 95%-CI 1.09–3.45), having more than two children in the same house (OR: 1.74; 95%-CI 1.12–2.71), and having been in contact with a close relative with COVID-19 (OR: 3.53; 95%-CI 2.24–5.58) were identified as risk factors for seropositivity in a multivariate analysis. A total of 47.5% of participants had received medication for COVID-19 treatment or prevention, and only ~50% of symptomatic subjects accessed PCR or antigenic testing. This study confirms a massive SARS-CoV-2 attack rate among HCWs in Cochabamba by the end of January 2021. The main risk factors identified are having a low-skilled job, living with children, and having been in contact with an infected relative in the household.
Collapse
Affiliation(s)
- Paola Mariela Saba Villarroel
- Aix-Marseille Univ, IRD 190, Inserm 1207, Unité des Virus Émergents (UVE), 27 Boulevard Jean Moulin, 13005 Marseille, France; (L.N.); (E.N.); (L.P.); (S.M.A.); (A.A.); (M.S.); (X.d.L.)
- Correspondence:
| | | | | | - Heydi Sanz
- Manuel Ascencio Villarroel Hospital, Cochabamba 4780, Bolivia;
| | | | - Laetitia Ninove
- Aix-Marseille Univ, IRD 190, Inserm 1207, Unité des Virus Émergents (UVE), 27 Boulevard Jean Moulin, 13005 Marseille, France; (L.N.); (E.N.); (L.P.); (S.M.A.); (A.A.); (M.S.); (X.d.L.)
| | - Elif Nurtop
- Aix-Marseille Univ, IRD 190, Inserm 1207, Unité des Virus Émergents (UVE), 27 Boulevard Jean Moulin, 13005 Marseille, France; (L.N.); (E.N.); (L.P.); (S.M.A.); (A.A.); (M.S.); (X.d.L.)
| | - Laura Pezzi
- Aix-Marseille Univ, IRD 190, Inserm 1207, Unité des Virus Émergents (UVE), 27 Boulevard Jean Moulin, 13005 Marseille, France; (L.N.); (E.N.); (L.P.); (S.M.A.); (A.A.); (M.S.); (X.d.L.)
| | - Souand Mohamed Ali
- Aix-Marseille Univ, IRD 190, Inserm 1207, Unité des Virus Émergents (UVE), 27 Boulevard Jean Moulin, 13005 Marseille, France; (L.N.); (E.N.); (L.P.); (S.M.A.); (A.A.); (M.S.); (X.d.L.)
| | - Abdennour Amroun
- Aix-Marseille Univ, IRD 190, Inserm 1207, Unité des Virus Émergents (UVE), 27 Boulevard Jean Moulin, 13005 Marseille, France; (L.N.); (E.N.); (L.P.); (S.M.A.); (A.A.); (M.S.); (X.d.L.)
| | - Morgan Seston
- Aix-Marseille Univ, IRD 190, Inserm 1207, Unité des Virus Émergents (UVE), 27 Boulevard Jean Moulin, 13005 Marseille, France; (L.N.); (E.N.); (L.P.); (S.M.A.); (A.A.); (M.S.); (X.d.L.)
| | - Xavier de Lamballerie
- Aix-Marseille Univ, IRD 190, Inserm 1207, Unité des Virus Émergents (UVE), 27 Boulevard Jean Moulin, 13005 Marseille, France; (L.N.); (E.N.); (L.P.); (S.M.A.); (A.A.); (M.S.); (X.d.L.)
| |
Collapse
|
11
|
Diarra I, Nurtop E, Sangaré AK, Sagara I, Pastorino B, Sacko S, Zeguimé A, Coulibaly D, Fofana B, Gallian P, Priet S, Drexler JF, Failloux AB, Dabo A, Thera MA, Djimdé A, Kouriba B, Cauchemez S, de Lamballerie X, Hozé N, Doumbo OK. Zika Virus Circulation in Mali. Emerg Infect Dis 2020; 26:945-952. [PMID: 32310065 PMCID: PMC7181926 DOI: 10.3201/eid2605.191383] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
The circulation of Zika virus (ZIKV) in Mali has not been clearly characterized. Therefore, we conducted a serologic survey of 793 asymptomatic volunteers >15 years of age (2016), and 637 blood donors (2013) to assess the seroprevalence of ZIKV infection in 2 ecoclimatic regions of Mali, tropical savannah and warm semiarid region, using ELISA and seroneutralization assays. The overall seroprevalence was ≈12% and increased with age, with no statistical difference between male and female participants. In the warm semiarid study sites we detected immunological markers of an outbreak that occurred in the late 1990s in 18% (95% CI 13%-23%) of participants. In tropical savannah sites, we estimated a low rate of endemic transmission, with 2.5% (95% CI 2.0%-3.1%) of population infected by ZIKV annually. These data demonstrate the circulation of ZIKV in Mali and provide evidence of a previously unidentified outbreak that occurred in the late 1990s.
Collapse
|
12
|
Nurtop E, Moyen N, Dzia-Lepfoundzou A, Dimi Y, Ninove L, Drexler JF, Gallian P, de Lamballerie X, Priet S. A Report of Zika Virus Seroprevalence in Republic of the Congo. Vector Borne Zoonotic Dis 2019; 20:40-42. [PMID: 31448988 DOI: 10.1089/vbz.2019.2466] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Zika virus (ZIKV) is an arthropod-borne RNA virus (arbovirus), belonging to the Spondweni serogroup. ZIKV was first described in Africa in 1947 and remained sporadic until Micronesia outbreak in 2007, which was followed by outbreaks in the Pacific Islands, Latin America, and the Caribbean. Subsequent to the epidemics, ZIKV revealed its severity as virus was sexually transmissible, and it was associated with serious fetal and neurological complications. ZIKV originated from Africa; however, little is known about the epidemiology of the virus in African populations. Following a recent study in Cameroon that evidenced low ZIKV epidemiology associated with a presumptive (peri-)sylvatic transmission, we performed a seroepidemiological study in Republic of the Congo, neighbor of Cameroon. To accomplish this, 386 serum specimens from volunteer blood donors collected in 2011 from rural and urban areas of Republic of the Congo were tested with ZIKV-specific methodology; primary screening with anti-NS1 ZIKV IgG ELISA followed by confirmation with cytopathic effect (CPE)-based virus neutralization test (VNT). ZIKV seropositivity was determined as low as 1.8%, varying slightly between urban and rural areas (1.7% and 3.6%). These results demonstrate that the majority of the population of Republic of the Congo is immunologically naïve against ZIKV with a presumptive (peri-)sylvatic transmission cycle, which emphasizes the importance of surveillance studies in Africa.
Collapse
Affiliation(s)
- Elif Nurtop
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France
| | - Nanikaly Moyen
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France
| | | | - Yannick Dimi
- Centre National de Transfusion Sanguine, Brazzaville, Republic of the Congo
| | - Laetitia Ninove
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France
| | - Jan Felix Drexler
- Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Pierre Gallian
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France.,Laboratoire de Virologie, Établissement Français du Sang Provence-Alpes Côte-d'Azur et Corse (EFS), Marseille, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France
| | - Stéphane Priet
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France
| |
Collapse
|
13
|
Nurtop E, Bayındır Bilman F, Menekse S, Kurt Azap O, Gönen M, Ergonul O, Can F. Promoters of Colistin Resistance in Acinetobacter baumannii Infections. Microb Drug Resist 2019; 25:997-1002. [PMID: 30964377 DOI: 10.1089/mdr.2018.0396] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Objectives: We aimed to describe the mechanisms of colistin resistance in Acinetobacter baumannii. Materials and Methods: Twenty-nine patients diagnosed with colistin-resistant A. baumannii infection were included to the study. The mutations in pmrCAB, lpxA, lpxC, and lpxD genes, expression of pmrCAB, carbapenemases, and mcr-1 positivity were studied. Results: Twenty-seven (93%) of the patients received IV colistin therapy during their stay, and the case fatality rate was 45%. All mutations in pmrC and pmrB were found to be accompanied with a mutation in lpxD. The most common mutations were I42V and L150F in pmrC (65%), E117K in lpxD (65%), and A138T in pmrB (58.6%). The colistin minimum inhibitory concentrations (MICs) of the isolates having any of these four mutations were higher than the isolates with no mutations (p < 0.001). The two most common mutations in pmrC (I42V and L150F) were found to be associated with higher expressions of pmrA and pmrC and higher colistin MIC values (p = 0.010 and 0.031). All isolates were blaOXA-23 positive. Conclusion: Coexistence of the lpxD mutation along with mutations in pmrCAB indicates synergistic function of these genes in development of colistin resistance in A. baumannii.
Collapse
Affiliation(s)
- Elif Nurtop
- Department of Medical Microbiology, School of Medicine, Koc University, Istanbul, Turkey
| | | | - Sirin Menekse
- Department of Infectious Diseases and Clinical Microbiology, Kosuyolu State Hospital, Istanbul, Turkey
| | - Ozlem Kurt Azap
- Department of Infectious Diseases and Clinical Microbiology, Baskent University School of Medicine, Ankara, Turkey
| | - Mehmet Gönen
- Department of Industrial Engineering, College of Engineering, Koc University, Istanbul, Turkey
| | - Onder Ergonul
- Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Koc University, Istanbul, Turkey
| | - Fusun Can
- Department of Medical Microbiology, School of Medicine, Koc University, Istanbul, Turkey
| |
Collapse
|
14
|
Nurtop E, Villarroel PMS, Pastorino B, Ninove L, Drexler JF, Roca Y, Gake B, Dubot-Peres A, Grard G, Peyrefitte C, Priet S, de Lamballerie X, Gallian P. Correction to: Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies. Virol J 2019; 16:12. [PMID: 30654811 PMCID: PMC6337804 DOI: 10.1186/s12985-019-1118-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Accepted: 01/08/2019] [Indexed: 11/26/2022] Open
Affiliation(s)
- Elif Nurtop
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France.
| | - Paola Mariela Saba Villarroel
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France.,Virología II, Centro Nacional de Enfermedades Tropicales (CENETROP), Santa Cruz de la Sierra, Bolivia
| | - Boris Pastorino
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France
| | - Laetitia Ninove
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France
| | - Jan Felix Drexler
- Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Yelin Roca
- Virología II, Centro Nacional de Enfermedades Tropicales (CENETROP), Santa Cruz de la Sierra, Bolivia
| | - Bouba Gake
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France.,Centre Pasteur du Cameroun, Yaoundé, Cameroon
| | - Audrey Dubot-Peres
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France
| | - Gilda Grard
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France.,National Reference Centre for Arboviruses, French Armed Forces Biomedical Research Institute, Marseille, France
| | - Christophe Peyrefitte
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France.,National Reference Centre for Arboviruses, French Armed Forces Biomedical Research Institute, Marseille, France
| | - Stéphane Priet
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France
| | - Pierre Gallian
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France.,Laboratoire de Virologie, Établissement Français du Sang Alpes Méditerranée (EFS), Marseille, France
| |
Collapse
|
15
|
Nurtop E, Villarroel PMS, Pastorino B, Ninove L, Drexler JF, Roca Y, Gake B, Dubot-Peres A, Grard G, Peyrefitte C, Priet S, de Lamballerie X, Gallian P. Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies. Virol J 2018; 15:192. [PMID: 30587193 PMCID: PMC6307276 DOI: 10.1186/s12985-018-1105-5] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2018] [Accepted: 12/04/2018] [Indexed: 12/21/2022] Open
Abstract
Here we propose a strategy allowing implementing efficient and practicable large-scale seroepidemiological studies for Zika Virus (ZIKV). It combines screening by a commercial NS1 protein-based Zika IgG ELISA, and confirmation by a cytopathic effect-based virus neutralization test (CPE-based VNT). In post-epidemic samples from Martinique Island blood donors (a population with a dengue seroprevalence above 90%), this strategy allowed reaching specificity and sensitivity values over 98%. The CPE-based VNT consists of recording CPE directly under the optical microscope, which is easy to identify with ZIKV strain H/PF/2013 at day 5 pi. Overall, considered that CPE-based VNT is cost effective and widely automatable, the NS1 protein-based Zika IgG ELISA+CPE-based VNT combination strategy represents a convenient tool to expedite ZIKV seroprevalence studies.
Collapse
Affiliation(s)
- Elif Nurtop
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
| | - Paola Mariela Saba Villarroel
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
- Virología II, Centro Nacional de Enfermedades Tropicales (CENETROP), Santa Cruz de la Sierra, Bolivia
| | - Boris Pastorino
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
| | - Laetitia Ninove
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
| | - Jan-Felix Drexler
- Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Yelin Roca
- Virología II, Centro Nacional de Enfermedades Tropicales (CENETROP), Santa Cruz de la Sierra, Bolivia
| | - Bouba Gake
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
- Centre Pasteur du Cameroun, Yaoundé, Cameroon
| | - Audrey Dubot-Peres
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
| | - Gilda Grard
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
- National Reference Centre for Arboviruses, French Armed Forces Biomedical Research Institute, Marseille, France
| | - Christophe Peyrefitte
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
- National Reference Centre for Arboviruses, French Armed Forces Biomedical Research Institute, Marseille, France
| | - Stéphane Priet
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
| | - Pierre Gallian
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
- Laboratoire de Virologie, Établissement Français du Sang Alpes Méditerranée (EFS), Marseille, France
| |
Collapse
|
16
|
Saba Villarroel PM, Nurtop E, Pastorino B, Roca Y, Drexler JF, Gallian P, Jaenisch T, Leparc-Goffart I, Priet S, Ninove L, de Lamballerie X. Zika virus epidemiology in Bolivia: A seroprevalence study in volunteer blood donors. PLoS Negl Trop Dis 2018. [PMID: 29513667 PMCID: PMC5858838 DOI: 10.1371/journal.pntd.0006239] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Background Zika virus (ZIKV), was widely reported in Latin America and has been associated with neuropathologies, as microcephaly, but only few seroprevalence studies have been published to date. Our objective was to determine the seroprevalence amongst Bolivian blood donors and estimate the future potential circulation of the virus. Methodology A ZIKV seroprevalence study was conducted between December 2016 and April 2017 in 814 asymptomatic Bolivian volunteer blood donors residing in various eco-environments corresponding to contrasting entomological activities. It was based on detection of IgG to ZIKV using NS1 ELISA screening, followed by a seroneutralisation test in case of positive or equivocal ELISA result. Conclusions/Significance Analysis revealed that ZIKV circulation occurred in tropical areas (Beni: 39%; Santa Cruz de la Sierra: 21.5%) but not in highlands (~0% in Cochabamba, La Paz, Tarija). It was modulated by Aedes aegypti activity and the virus spread was not limited by previous immunity to dengue. Cases were geo-localised in a wide range of urban areas in Santa Cruz and Trinidad. No differences in seroprevalence related to gender or age-groups could be identified. It is concluded that ZIKV has been intensely circulating in the Beni region and has still a significant potential for propagating in the area of Santa Cruz. Zika virus (ZIKV) is a virus of African origin, transmitted by Aedes mosquitoes, and related to dengue and yellow fever virus. It was originally believed to be responsible for a mild febrile illness in Africa and South-east Asia. However, in recent years, ZIKV has been responsible for outbreaks in the Pacific Islands before massively spreading in Latin America and the Caribbean. On this occasion, ZIKV has unexpectedly been associated with non-vector transmission (i.e., sexual and mother-to-foetus transmission) and with severe complications such as foetal abnormalities (e.g. microcephaly) and Guillain-Barré syndromes. Little is known about the actual proportion of the populations infected by ZIKV in Latin America. Here, we report a seroprevalence data in this region, after studying 814 asymptomatic Bolivian volunteer blood donors residing in various eco-environments corresponding to contrasting entomological activities. We conclude that ZIKV has been circulating in Bolivian tropical areas but not in highlands, and that the epidemic has not been limited by previous immunity against dengue. Specific attention should be paid to the region of Santa Cruz, where the seroprevalence is still limited, but the density of Aedes aegypti populations makes plausible further spreading of the disease.
Collapse
Affiliation(s)
- Paola Mariela Saba Villarroel
- UMR EPV Émergence des Pathologies Virales, Aix-Marseille University—IRD 190—Inserm 1207 –EHESP–IHU Méditerranée Infection, Marseille, France
- Virología II, Centro Nacional de Enfermedades Tropicales (CENETROP), Santa Cruz de la Sierra, Bolivia
- * E-mail:
| | - Elif Nurtop
- UMR EPV Émergence des Pathologies Virales, Aix-Marseille University—IRD 190—Inserm 1207 –EHESP–IHU Méditerranée Infection, Marseille, France
| | - Boris Pastorino
- UMR EPV Émergence des Pathologies Virales, Aix-Marseille University—IRD 190—Inserm 1207 –EHESP–IHU Méditerranée Infection, Marseille, France
| | - Yelin Roca
- Virología II, Centro Nacional de Enfermedades Tropicales (CENETROP), Santa Cruz de la Sierra, Bolivia
| | - Jan Felix Drexler
- German Centre for Infection Research (DZIF) Charité—Universitätsmedizin Berlin, Berlin, Germany
- Institute of Virology, Charité—Universitätsmedizin Berlin, Berlin, Germany
| | - Pierre Gallian
- Laboratoire de Virologie, Établissement Français du Sang Alpes Méditerranée (EFS), Marseille, France
| | - Thomas Jaenisch
- Department for Infectious Diseases (Section Clinical Tropical Medicine), Heidelberg University Hospital, Heidelberg, Germany
| | - Isabelle Leparc-Goffart
- National Reference Centre for Arboviruses, French Armed Forces Biomedical Research Institute, Marseille, France
| | - Stéphane Priet
- UMR EPV Émergence des Pathologies Virales, Aix-Marseille University—IRD 190—Inserm 1207 –EHESP–IHU Méditerranée Infection, Marseille, France
| | - Laetitia Ninove
- UMR EPV Émergence des Pathologies Virales, Aix-Marseille University—IRD 190—Inserm 1207 –EHESP–IHU Méditerranée Infection, Marseille, France
| | - Xavier de Lamballerie
- UMR EPV Émergence des Pathologies Virales, Aix-Marseille University—IRD 190—Inserm 1207 –EHESP–IHU Méditerranée Infection, Marseille, France
| |
Collapse
|
17
|
Can F, Kurt-Azap O, Nurtop E, Ispir P, Seref C, Ergonul O. Molecular epidemiology of bloodstream-associated Escherichia coli ST131 H30-Rx subclone infection in a region with high quinolone resistance. J Med Microbiol 2016; 65:306-310. [PMID: 26795934 DOI: 10.1099/jmm.0.000224] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Bloodstream infections caused by Escherichia coli ST131 and ST131 H30-Rx subclones have emerged worldwide. This study was carried out to evaluate the prevalence of the ST131-Rx subclone and characterize the virulence properties of the Rx isolates among the bloodstream E. coli isolates. A total of 297 non-duplicated E. coli bloodstream isolates were studied. Antibiotic susceptibilities were tested using the disc diffusion method. PCR amplification and sequencing was used to identify ST131 and H30-Rx, the virulence gene, the β-lactamase and virotype. Quinolone resistance among bacteraemic E. coli strains was 51 %, and it was 98 % among E. coli ST131 isolates. The ST131 isolates accounted for 16 % (49) of all isolates and all ST131 isolates belonged to the extraintestinal pathogenic E. coli. The proportion of H30 subclone among the ST131 isolates was 98 %, and 75 % of H30 isolates belonged to the H30-Rx subclone. The prevalence of ST131 increased from 13 to 23 % in 4 years; however, there was a decrease in the ratio of H30-Rx infections. CTX-M-15 was detected in 85 % of ST131 and all of the H30-Rx isolates. The virulence genes associated with adhesion, cell protection, iron uptake and toxins (papA, iha, kpsMTII, iut and sat) were more common in ST131 than in non-ST131 isolates. Most of the ST131 and H30-Rx isolates were of the C virotype. All papA-positive isolates were in virotype C. The E. coli ST131 clone has increased rapidly among bloodstream isolates. However, a decrease in the proportion of the H30-Rx subclone in the quinolone-resistant population suggests the possibility of dissemination of other virulent and quinolone-resistant subclones in hospital settings.
Collapse
Affiliation(s)
- Fusun Can
- Koc University, School of Medicine, Clinical Microbiology Department, Istanbul, Turkey
| | - Ozlem Kurt-Azap
- Baskent University, School of Medicine, Department of Infectious Diseases, Ankara, Turkey
| | - Elif Nurtop
- Koc University, School of Medicine, Clinical Microbiology Department, Istanbul, Turkey
| | - Pelin Ispir
- Koc University, School of Medicine, Clinical Microbiology Department, Istanbul, Turkey
| | - Ceren Seref
- Koc University, School of Medicine, Clinical Microbiology Department, Istanbul, Turkey
| | - Onder Ergonul
- Koc University, School of Medicine, Infectious Diseases Department, Istanbul, Turkey
| |
Collapse
|
18
|
Can F, Kurt-Azap Ö, İspir P, Nurtop E, Seref C, Loçlar İ, Aktaş ON, Orhan YC, Ergonul O. The clinical impact of ST131 H30-Rx subclone in urinary tract infections due to multidrug-resistant Escherichia coli. J Glob Antimicrob Resist 2015; 4:49-52. [PMID: 27436393 DOI: 10.1016/j.jgar.2015.10.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Revised: 10/03/2015] [Accepted: 10/07/2015] [Indexed: 10/22/2022] Open
Abstract
In this study, risk factors for ST131 H30 and H30-Rx subclones among urinary tract infections (UTIs) caused by multidrug-resistant (MDR) Escherichia coli were described. Urine samples were collected from consecutive outpatients registered to the outpatient clinics of Başkent University Hospital (Ankara, Turkey) with complaints of acute cystitis in 2011. A total of 107 MDR E. coli isolates were included in the study. Of the 107 isolates studied, 26 (24.3%) were typed as ST131 clone. Extended-spectrum β-lactamase (ESBL)-producers accounted for 59 (55.1%) of the 107 isolates. Among the 59 ESBL-positive isolates, 18 (31%) were found to belong to the ST131 clone. Of the 18 ESBL-positive ST131 isolates, 17 (94%) were defined as H30 subclone, among which 16 (94%) represented the H30-Rx subclone. Among the 48 ESBL-negative isolates, 8 (17%) ST131 isolates were detected, 7 (88%) of which belonged to H30 subclone; 5 (71%) of the H30 subclone isolates were classified under H30-Rx subclone. In multivariate analysis, hospitalisation within last year was the only host risk factor associated with MDR E. coli ST131 H30-Rx subclone UTI (OR=3.5, 95% CI 1.04-12.17; P=0.042). CTX-M-15 production was found to be highly associated with the presence of ST131 H30-Rx subclone (OR=4.8, 95% CI 1.54-15.32; P=0.007). In conclusion, urinary MDR E. coli ST131 H30-Rx subclone was found to be important in the dissemination of MDR UTIs in the community. Approximately 20% of the MDR isolates were H30-Rx subclone. Infection with this subclone was found to be healthcare-associated.
Collapse
Affiliation(s)
- Fusun Can
- Clinical Microbiology Department, School of Medicine, Koç University, Istanbul, Turkey
| | - Özlem Kurt-Azap
- Department of Infectious Diseases, School of Medicine, Başkent University, Ankara, Turkey
| | - Pelin İspir
- Clinical Microbiology Department, School of Medicine, Koç University, Istanbul, Turkey
| | - Elif Nurtop
- Clinical Microbiology Department, School of Medicine, Koç University, Istanbul, Turkey
| | - Ceren Seref
- Clinical Microbiology Department, School of Medicine, Koç University, Istanbul, Turkey
| | - İlayda Loçlar
- School of Medicine, Koç University, Istanbul, Turkey
| | | | | | - Onder Ergonul
- Infectious Diseases Department, School of Medicine, Koç University, Sarıyer, Istanbul, Turkey.
| |
Collapse
|